Frequently asked questions

What does a GHK-Cu peptide do?

In the studied sense, GHK-Cu acts on the material tissue is made of. It stimulates dermal fibroblasts to synthesise collagen, elastin, glycosaminoglycans and the small proteoglycan decorin, and at the same time rebalances matrix metalloproteinases — the enzymes that break matrix down — against their TIMP inhibitors ^[4]. The copper it carries is required by lysyl oxidase to cross-link collagen and elastin into load-bearing fibre.

A broader remodeling review adds that it increases VEGF, FGF-2 and nerve growth factor and anti-proteases while suppressing free radicals and the signalling proteins TGF-beta-1 and TNF-alpha, and chemoattracts repair cells into injured tissue ^[9]. In measured human terms, the clearest result is a procollagen one: synthesis increased in 70% of GHK-Cu-treated subjects against 50% for vitamin C and 40% for retinoic acid ^[1].

What is GHK-Cu and how does it work?

GHK-Cu is a three-amino-acid peptide — glycine, histidine, lysine — bound one-to-one to a copper(II) ion. The sequence is not foreign to the body: it occurs inside the alpha-2(I) chain of type I collagen and in the matrix protein SPARC/osteonectin, and free GHK circulates in plasma at levels that fall with age, from roughly 200 ng/mL at twenty to about 80 ng/mL by sixty ^[4].

It works in two ways at once. As a copper chaperone it delivers the metal that cross-linking and antioxidant enzymes require. As a signalling molecule, at picomolar-to-nanomolar concentrations, it changes what fibroblasts build and how quickly existing matrix is turned over ^[4][9]. Gene-expression analysis reports it modulating about 31.2% of human genes at a 50%-or-greater change threshold, with strong stimulation of protein-clearance, DNA-repair and antioxidant gene sets ^[2].

Is GHK-Cu peptide really anti-aging?

That depends entirely on what the phrase is taken to mean, and the honest answer splits in two.

For measurable skin outcomes applied topically, there is real controlled evidence: placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density, and a procollagen increase in 70% of treated subjects ^[1][4]. That is a genuine result in a narrow lane.

For anything broader — systemic rejuvenation, slowed biological ageing — the evidence does not currently reach. The gene-expression work is striking but derives largely from database analysis that still needs protein-level validation in living tissue ^[2], and the widely repeated "about 4,000 genes" figure is an extrapolation rather than a measurement; the table at the stated threshold reports on the order of 2,100 genes. The plasma decline with age is an observation, not a demonstrated cause. Much of the foundational literature also comes from a limited number of research groups, so independent replication of the broad claims is thin.

What is the difference between GHK and GHK-Cu?

GHK is the bare tripeptide glycyl-L-histidyl-L-lysine. GHK-Cu is that same tripeptide chelated to a copper(II) ion, held through the histidine imidazole nitrogen, the glycine alpha-amino nitrogen and the deprotonated glycine-histidine amide nitrogen.

The difference is not cosmetic. Most of the documented tissue-remodeling activity depends on the copper actually being bound — the plain peptide does not reproduce key effects, including metalloproteinase-2 stimulation, in cell studies. Tight copper binding also matters for safety: the intact complex holds the metal firmly enough to keep it from acting as a loose pro-oxidant, and a degraded or destabilised product loses that protection.

Because the literature frequently uses the two names interchangeably, the first question to ask of any GHK claim is which form was actually tested.

What is GLOW peptide?

GLOW is not a single peptide. It is a co-formulated research blend — a vial holding three different peptides mixed together — assembled by suppliers and clinics rather than manufactured to any approved or standardised formula.

The rationale behind it is that tissue repair happens in stages, and the three peptides act at different stages: one supports the blood supply, one promotes cell migration into the wound, and one builds and cross-links matrix. Covering several stages at once is the pitch.

What does not exist is any test of that pitch. There is no controlled clinical trial of the GLOW combination for any indication, so every claim made for it is transferred from research on its individual constituents ^[6].

What does the GLOW peptide do?

Nothing has been measured for the blend itself, so the accurate answer describes what its parts do separately.

The GHK-Cu component stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and decorin and is associated with tighter, more elastic skin and reduced fine lines in the review literature ^[4]. The BPC-157 component is pro-angiogenic through VEGFR2 up-regulation and VEGFR2-Akt-eNOS signalling, raising vessel density in cell and animal models ^[8]. The TB-500 component derives from thymosin beta-4, which increased re-epithelialisation by 42% at day four and 61% at day seven in a rat wound model, and raised wound contraction, collagen deposition and angiogenesis ^[11].

Those are three separate findings in three separate settings. Combining the compounds does not combine the evidence, and the one review naming all three together concluded that rigorous human safety data in this class are scarce ^[6].

What does GLOW peptide have in it?

A GLOW vial most commonly contains three research peptides: GHK-Cu, BPC-157 and TB-500.

Quantities are the part that cannot be pinned down. Ratios are formulation-specific and not standardised, varying by whoever mixed the vial; suppliers publish fixed milligram ratios, but those figures come from the market rather than from any controlled human trial and carry no validated basis. Purity and actual content are likewise unverified outside formal analysis, because none of this moves through a regulated supply chain.

That variability is itself a reason to treat blend-level claims cautiously: two vials sold under the same name need not contain the same thing in the same proportion.

What peptides are in the GLOW blend?

Three, each from a different corner of the repair literature.

GHK-Cu — the copper(II) chelate of glycyl-L-histidyl-L-lysine, a matrix-remodeling and collagen-stimulating copper peptide.

BPC-157 — a stable fifteen-amino-acid peptide derived from a gastric body-protection protein, described as cytoprotective and pro-angiogenic.

TB-500 — an acetylated seven-amino-acid fragment corresponding to the actin-binding region of thymosin beta-4, associated with cell migration and reduced scarring.

One caveat belongs specifically to the third. Commercial TB-500 is the short fragment, whereas most published efficacy data uses full-length thymosin beta-4 ^[11], and it is not established that the fragment reproduces what the parent protein does. Evidence borrowed from thymosin beta-4 studies is therefore borrowed at one further remove than it appears.

What does BPC-157 do in the body?

The repair effects reported in animals are most consistently linked to angiogenesis, the growth of new blood vessels. The best-characterised route is up-regulation of the VEGFR2 receptor and promotion of its internalisation in vascular endothelial cells, with downstream VEGFR2-Akt-eNOS signalling; the reported results include greater vessel density and faster blood-flow recovery in ischaemic muscle ^[8]. Additional reported routes include the FAK-paxillin complex in cell migration, sensitisation of the growth hormone receptor in tendon fibroblasts, and modulation of the nitric-oxide and several neurotransmitter systems.

In animal models that translates into faster healing across quite different tissues: reduced gastric ulcer area with accelerated glandular-epithelium rebuilding and granulation-tissue formation in rats ^[14], and accelerated healing of a fully transected rat Achilles tendon ^[10].

The important qualifier is species. Those are animal findings, and the human record consists of three small pilot studies ^[7].

Is BPC-157 a growth hormone?

No. BPC-157 is a synthetic fifteen-amino-acid peptide copied from part of a protein found in human gastric juice — a body-protection compound, not a hormone, and not a growth-hormone secretagogue.

One reported mechanism does touch that system, which may be where the confusion originates: in cultured tendon cells, BPC-157 increased growth-hormone-receptor signalling, and that sensitisation is thought to be part of how it influences tissue repair. Making a receptor more responsive is not the same as being the hormone that acts on it, and nothing in the literature describes BPC-157 raising growth hormone levels.

Related claims that circulate online — that it builds muscle, causes weight loss, or raises testosterone — are not supported by the published evidence.

Does BPC-157 work immediately?

The pharmacokinetics and the reported outcomes sit on completely different clocks, and the mismatch is worth understanding.

The molecule itself does not linger. Formal characterisation in rats and dogs found an elimination half-life under thirty minutes, with rapid breakdown into small fragments entering ordinary amino-acid metabolism ^[13]. The healing outcomes, by contrast, were measured over days and weeks — ulcer healing and granulation tissue in rats ^[14], tendon recovery across biomechanical and functional measures ^[10].

So whatever the peptide contributes has to be initiated quickly and then carried forward by the tissue itself; the compound is long gone while the repair it is credited with is still under way. Community accounts describing improvement within one to three weeks are anecdotal, not clinical evidence, and there is no human efficacy trial against which to check any timeline at all ^[7].

Does BPC-157 damage the liver?

There is no published evidence that it does, and — importantly — there is also not enough human data to state that it does not.

The one relevant human measurement comes from a first-in-human intravenous safety pilot: BPC157 at up to 20 mg given to two healthy adults was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[12]. Hepatic biomarkers were among the things checked, and nothing moved. The sample was two people.

Animal pharmacokinetic work found the peptide broken down into small fragments that enter normal amino-acid metabolism, with excretion via urine and bile ^[13].

Reassuring as far as it goes, and it does not go far. A 2025 review concluded that rigorous large-scale trials are lacking and that the compound should be treated as investigational ^[7]; with no long-term human safety data, the accurate position on organ safety is unknown rather than established. A separate and more practical risk is product identity: because the compound moves through non-regulated channels, what is actually in a given vial is unverified.